U.S. markets closed

Magenta Therapeutics, Inc. (MGTA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.1900-0.0500 (-4.03%)
At close: 04:00PM EST
1.1900 0.00 (0.00%)
After hours: 05:23PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.2400
Bid1.1900 x 1800
Ask1.2600 x 3000
Day's Range1.1700 - 1.2500
52 Week Range0.9200 - 5.8600
Avg. Volume180,839
Market Cap72.061M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-1.3320
Earnings DateMar 06, 2023 - Mar 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MGTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Magenta Therapeutics, Inc.
    Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 3Q22. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings (among others) in order to determine their core holdings and new purchases. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of Activist investors, according to Vickers.
    Fair Value
    Economic Moat
    15 days agoArgus Research
View more
  • GlobeNewswire

    Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

    – New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presentation of clinical data will be given at the 2022 American Society of Hematology (ASH) meeting in December 2022 – – CD45 antibody-drug conjugate (ADC) dose-ranging toxicology study successfully completed; IND-enabling st

  • GlobeNewswire

    Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

    – Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism – – Poster presentation of data from a MGTA-117 non-human primate study that has provided predictive modeling of biologic activity in the ongoing Phase 1/2 dose escalation clinical trial – – Poster presentation of MGTA-145 “trial-in-progress” abstract describing the clinical trial design for mobilization and collection of stem cells from patients with sic

  • GlobeNewswire

    Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

    CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Credit Suisse 31st Annual Healthcare Conference being held November 7-10, 2022. The webcast of Magenta's presentation will be accessible at 8:00am Pacific Time on Tuesday, November 8, 2022 on the Magenta Therapeut